cosibelimab
Marketedupdated 2mo agoby Checkpoint Therapeutics Inc
Approvedcommunity read0 votes
Antibody drug with a maximum clinical stage of Approval (across all indications), with an approval for head and neck squamous cell carcinoma and 2 investigational indications.
all catalysts(2)
News(0)
no news has mentioned this drug yet
comments(0)
5-min edit window · permanent after that